|
Volumn 16, Issue 1, 2014, Pages 165-
|
Challenging cytomegalovirus data in glioblastoma
|
Author keywords
[No Author keywords available]
|
Indexed keywords
EARLY ANTIGEN;
VALGANCICLOVIR;
ANTIVIRUS AGENT;
GANCICLOVIR;
CANCER PROGNOSIS;
CANCER THERAPY;
COMPASSIONATE USE;
CYTOMEGALOVIRUS;
CYTOMEGALOVIRUS INFECTION;
DRUG EXPOSURE;
GLIOBLASTOMA;
HUMAN;
LETTER;
LONG TERM CARE;
PATIENT SELECTION;
PROTEIN EXPRESSION;
ANALOGS AND DERIVATIVES;
BRAIN NEOPLASMS;
CLINICAL TRIAL (TOPIC);
COMPLICATION;
PATHOGENICITY;
PROGNOSIS;
VIROLOGY;
ANTIVIRAL AGENTS;
BRAIN NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
CYTOMEGALOVIRUS;
CYTOMEGALOVIRUS INFECTIONS;
GANCICLOVIR;
GLIOBLASTOMA;
HUMANS;
PATIENT SELECTION;
PROGNOSIS;
|
EID: 84891553747
PISSN: 15228517
EISSN: 15235866
Source Type: Journal
DOI: 10.1093/neuonc/not212 Document Type: Letter |
Times cited : (10)
|
References (5)
|